p.104 抽出テキスト

808. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J 2024;45:4063–98. https://doi.org/10.1093/ eurheartj/ehae508 809. Obokata M, Reddy YNV, Melenovsky V, Sorimachi H, Jarolim P, Borlaug BA. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail 2022;24: 353–61. https://doi.org/10.1002/ejhf.2377 810. Corrà U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC. Eur J Heart Fail 2014;16:929–41. https://doi.org/10.1002/ejhf.156 811. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol 2017;69:1129–42. https://doi.org/10.1016/j.jacc. 2016.11.081 812. Larson K, Omar M, Sorimachi H, Omote K, Alogna A, Popovic D, et al. Clinical phenogroup diversity and multiplicity: impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Eur J Heart Fail 2024;26:564–77. https://doi.org/10.1002/ejhf.3105 813. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19. https://doi. org/10.1161/CIRCULATIONAHA.116.026807 814. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 2018;71: 2360–72. https://doi.org/10.1016/j.jacc.2018.03.509 815. Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, et al. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail 2020;22: 1009–18. https://doi.org/10.1002/ejhf.1788 816. Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 2019;94: 1199–209. https://doi.org/10.1016/j.mayocp.2018.11.037 817. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2016;315: 36–46. https://doi.org/10.1001/jama.2015.17346 818. Lee VYJ, Houston L, Perkovic A, Barraclough JY, Sweeting A, Yu J, et al. The effect of weight loss through lifestyle interventions in patients with heart failure with preserved ejection fraction—a systematic review and meta-analysis of randomised controlled trials. Heart Lung Circ 2024;33:197–208. https:// doi.org/10.1016/j.hlc.2023.11.022 819. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 2024; 404:773–86. https://doi.org/10.1016/S0140-6736(24)01498-3 820. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404: 949–61. https://doi.org/10.1016/S0140-6736(24)01643-X 821. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–8. https://doi.org/10.1001/jama.2016.10260 822. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19:69–77. https://doi.org/10.1002/ejhf.657 823. Mentias A, Desai MY, Aminian A, Patel KV, Keshvani N, Verma S, et al. Trends and outcomes associated with bariatric surgery and pharmacotherapies with weight loss effects among patients with heart failure and obesity. Circ Heart Fail 2024;17:e010453. https://doi.org/10.1161/CIRCHEARTFAILURE.122. 010453 824. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JE, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation 2021;143:1468–80. https://doi.org/10.1161/ CIRCULATIONAHA.120.052386 825. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635–48. https:// doi.org/10.1016/S0140-6736(24)00469-0 826. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017–20. https://doi.org/10.1016/s0002-9149(97)89163-1 827. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:54–65. https://doi.org/10. 1002/ejhf.679 828. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017;40: 671–8. https://doi.org/10.2337/dc16-2016 829. Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med 2024;30:3758–64. https://doi.org/10.1038/s41591- 024-03264-4 830. Böhm M, Pogue J, Kindermann I, Poss J, Koon T, Yusuf S. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. Eur J Heart Fail 2014;16:325–33. https://doi.org/10.1002/ejhf.23 831. Jackson AM, Rørth R, Liu J, Kristensen SL, Anand IS, Claggett BL, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2022;24:497–509. https://doi.org/10.1002/ ejhf.2403 832. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146:848–53. https://doi.org/10.1016/S0002-8703(03)00403-4 833. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016;9:e002560. https://doi.org/10. 1161/CIRCHEARTFAILURE.115.002560 834. Butler J, Anker SD, Filippatos G, Usman MS, Ferreira JP, Zannad F, et al. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. Eur Heart J 2021;42:4887–90. https://doi. org/10.1093/eurheartj/ehab704 835. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium–glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:1755–61. https://doi.org/10.1111/ dom.13260 836. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337–48. https://doi.org/10.1056/NEJMoa1708337 837. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395–402. https://doi.org/10. 1161/CIRCHEARTFAILURE.112.000162 838. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345–51. https://doi.org/10.2337/ diacare.28.10.2345 839. Andersson C, Olesen JB, Hansen PR, Weeke P, Nørgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010;53:2546–53. https://doi.org/10.1007/s00125-010- 1906-6 840. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Sævereid HA, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. https://doi.org/10.1186/s12933-019-0960-8 841. Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–28. https://doi.org/10.1056/NEJMoa1203858 842. Gerstein HC, Jung H, Ryden L, Diaz R, Gilbert RE, Yusuf S, et al. Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (outcome reduction with initial glargine intervention). Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026